Quince Therapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Quince Therapeutics, Inc. (NASDAQ: QNCX) is a late-stage biopharmaceutical company focused on acquiring, developing, and commercializing innovative therapeutics that leverage a patient's own biology for the treatment of rare and debilitating diseases. The company utilizes its proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, a novel drug/device combination that employs an automated process to encapsulate therapeutics into a patient's own red blood cells for targeted delivery and reduced toxicity; its lead product candidate, eDSP (previously EryDex), comprises dexamethasone sodium phosphate (DSP), a corticosteroid, encapsulated in autologous erythrocytes for the treatment of Ataxia-Telangiectasia (A-T), a rare pediatric neurodegenerative and immunodeficiency disorder caused by ATM gene mutations. eDSP aims to deliver the anti-inflammatory benefits of corticosteroids while minimizing associated serious adverse effects such as adrenal suppression; the platform supports expansion into additional indications including Duchenne muscular dystrophy (DMD), inflammatory bowel disease (Crohn's disease and ulcerative colitis), chronic obstructive pulmonary disease (COPD), and cystic fibrosis, with over 7,800 infusions administered to approximately 425 patients across prior clinical trials and expanded access programs, including 188 patients treated for at least 12 months without typical corticosteroid toxicities. Founded in 2012 and headquartered in South San Francisco, California, Quince Therapeutics operates primarily in the United States and Italy, with corporate offices and a manufacturing facility in Italy through its subsidiary Quince Therapeutics S.p.A. The company targets patients with rare diseases and chronic conditions requiring safer corticosteroid therapies, with no approved treatments currently available for A-T in any global market. Recent major developments include the completion of enrollment in July 2025 for its pivotal Phase 3 NEAT clinical trial evaluating eDSP in 105 A-T patients (83 aged 6-9 years in the primary analysis population and 22 aged 10+ years), conducted under a U.S. FDA Special Protocol Assessment that supports a potential New Drug Application submission upon positive results, with topline data expected in the first quarter of 2026; the FDA also granted Fast Track designation for eDSP in A-T. In 2023, Quince completed the acquisition of EryDel S.p.A., securing rights to the Phase 3-ready EryDex asset (now eDSP) and enhancing its AIDE platform capabilities. In June 2025, the company closed a private placement financing of up to $22 million (including $11.5 million upfront led by Nantahala Capital with participation from ADAR1 Capital Management and management), extending its cash runway into mid-2026 to support NEAT trial completion and topline readout. Quince plans to prioritize capital for eDSP in A-T while evaluating eDSP for DMD and further pipeline expansion using the AIDE platform.
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript
UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
Quince Therapeutics Settles Approximately $16.4 Million of Debt
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of “Reduce” by Analysts
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of “Reduce” by Analysts
What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours
Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks
Investors Purchase Large Volume of Quince Therapeutics Call Options (NASDAQ:QNCX)
Quince Therapeutics Stock Explodes 300% On Strategic Review
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Rating of “Moderate Buy” from Brokerages
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of “Moderate Buy” from Analysts